Management of cardiovascular risk in primary prevention: real-world data

被引:0
|
作者
Danchin, N. [1 ]
Puymirat, E. [1 ]
Vedrenne, G. [1 ]
Durand, E. [1 ]
机构
[1] Hop Europeen Georges Pompidou, Dept Cardiol, 20 Rue Leblanc, F-75015 Paris, France
关键词
Primary prevention; Statins; Antihypertensive agents; Tobacco ban; Diabetes; Obesity;
D O I
10.1016/S1878-6480(12)70843-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tremendous progress in the management of cardiovascular risk in the general population has been accomplished over the past two decades, resulting in a decreased incidence of severe cardiovascular conditions such as myocardial infarction, and in a dramatic reduction in cardiovascular mortality. In particular, the management of hypertension and hyperlipidaemia have notably improved. Among public health measures, the smoking ban has been largely successful, while nutritional campaigns and the fight against sedentary behaviours have given mixed results, with continuing growth in the proportion of overweight and obese individuals in the general population. It is therefore essential that recent efforts at prevention are pursued to ensure that the incidence of cardiovascular disease will not rise again in the future. (C) 2012 Elsevier Masson SAS. All rights reserved.
引用
下载
收藏
页码:279 / 283
页数:5
相关论文
共 50 条
  • [31] Brain metastases in primary ovarian cancer: Real-world data
    Ratner, E.
    Bala, M.
    Louie-Gao, M.
    Hazard, S.
    Brastianos, P.
    ANNALS OF ONCOLOGY, 2018, 29 : 338 - 338
  • [32] Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence
    Gliklich, Richard E.
    Leavy, Michelle B.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (02) : 303 - 307
  • [33] Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence
    Richard E. Gliklich
    Michelle B. Leavy
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 303 - 307
  • [34] Contributions of Real-World Evidence and Real-World Data to Decision-Making in the Management of Soft Tissue Sarcomas
    Demetri, George D.
    Stacchiotti, Silvia
    ONCOLOGY, 2021, 99 (SUPPL 1) : 3 - 7
  • [35] Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence
    Toth, Peter P.
    Fazio, Sergio
    Wong, Nathan D.
    Hull, Michael
    Nichols, Gregory A.
    DIABETES OBESITY & METABOLISM, 2020, 22 (03): : 279 - 289
  • [36] Stroke Prevention in Atrial Fibrillation What Is Real World, and What Do Real-World Data Reveal?
    Healey, Jeff S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (02) : 154 - 155
  • [37] The dynamic risk factors of cardiovascular disease among people living with HIV: a real-world data study
    Liu, Ziang
    Zhang, Jiajia
    Yang, Xueying
    Gao, Haoyuan
    Chen, Shujie
    Weissman, Sharon
    Olatosi, Bankole
    Li, Xiaoming
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [38] Real-world cardiovascular outcomes of atazanavir
    Rosenblatt, L.
    Farr, A. M.
    Nkhoma, E.
    Nelson, J. K.
    Ritchings, C.
    Johnston, S.
    ANTIVIRAL THERAPY, 2015, 20 : A60 - A60
  • [39] Comparative effectiveness of antihypertensive monotherapies in primary prevention of cardiovascular events-a real-world longitudinal inception cohort study
    Li, Xuechun
    Bijlsma, Maarten J.
    de Vos, Stijn
    Bos, Jens H. J.
    Mubarik, Sumaira
    Schuiling-Veninga, Catharina C. M.
    Hak, Eelko
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [40] Inaccurate Real-World Data Does Not Provide Real-World Answers
    Buffet, Gabriela
    Mendoza-Sassi, Raul
    Fysekidis, Marinos
    AMERICAN JOURNAL OF THERAPEUTICS, 2021, 28 (05) : E596 - E598